| Property |
Value |
| Drug Name |
Rotigotine |
| Brand Name |
Neupro |
| Drug Class |
Dopamine Agonist |
| Target |
D1, D2, D3 Dopamine Receptors |
| Route of Administration |
Transdermal Patch |
| FDA Approval |
2007 (PD), 2008 (RLS) |
| Company |
UCB Pharma |
Rotigotine (Neupro) is a transdermal dopamine agonist used in the treatment of Parkinson's disease (PD) and Restless Legs Syndrome (RLS). It is administered via a once-daily patch that provides continuous dopaminergic stimulation, offering advantages over oral dopamine agonists in terms of stable plasma concentrations and reduced motor complications.
Rotigotine is a selective dopamine agonist that acts primarily on D1, D2, and D3 dopamine receptors:
- Receptor Activation: Direct agonist at D1 (excitatory) and D2/D3 (inhibitory) dopamine receptors
- Full Agonist: Activates dopamine receptors with efficacy similar to endogenous dopamine
- Selectivity: Higher affinity for D3 receptor compared to other dopamine agonists
- Continuous Delivery: 24-hour constant drug release avoids peaks and troughs
- Improved Tolerability: Reduces dopamine agonist-related side effects (nausea, somnolence)
- Stable Plasma Levels: Maintains therapeutic concentrations throughout the day
- Easy Administration: Simple patch application improves adherence
- Onset of Action: Therapeutic effect within 1-2 hours of patch application
- Steady State: Achieved within 2-3 days of continuous use
- Half-life: 5-7 hours (parent drug), longer due to transdermal delivery
- Metabolism: Hepatic via CYP enzymes (CYP2D6, CYP3A4)
- Indication: Initial treatment for early-stage PD
- Benefits: Delays need for levodopa, may reduce motor complications
- Dosing: Start at 2 mg/24h, titrate to 8 mg/24h maximum
- Indication: Adjunct to levodopa in advanced PD
- Benefits: Reduces "off" time, improves "on" time with less dyskinesia
- Dosing: 4-8 mg/24h in combination with levodopa
- Indication: Moderate to severe primary RLS
- Benefits: Reduces RLS symptoms, improves sleep quality
- Dosing: Start at 1 mg/24h, titrate to 3 mg/24h
| Target |
Receptor Subtype |
Clinical Effect |
| D1 |
D1, D5 |
Motor activation |
| D2 |
D2S, D2L |
Motor inhibition, psychosis modulation |
| D3 |
D3 |
Motivation, reward, gait control |
- Motor Symptoms: Significant improvement in UPDRS Part II (ADL) and Part III (motor) scores
- Motor Complications: Reduced "off" time by 1.5-2.5 hours/day
- Dyskinesia: Lower incidence compared to oral dopamine agonists (in some studies)
- Quality of Life: Improved PDQ-39 scores
- Symptom Reduction: IRLS scale improvement of 40-60% vs baseline
- Sleep Quality: Improved sleep quality and duration
- Response Rate: ~70% of patients achieve clinically meaningful response
¶ Side Effects and Safety
- Application Site Reactions: Pruritus, erythema (most common)
- Nausea: Usually mild, resolves with continued treatment
- Somnolence: May cause drowsiness, caution when driving
- Headache: Usually mild and transient
- Hallucinations: More common in elderly and those with cognitive impairment
- Impulse Control Disorders: Pathological gambling, shopping, eating (rare)
- Sleep Attacks: Sudden sleep onset (rare but serious)
- Melanoma: Slightly increased risk (observed in some studies)
- Hypotension: Orthostatic hypotension, especially when initiating
- Psychosis: May worsen pre-existing psychosis
- Antipsychotics: May reduce efficacy (dopamine antagonists)
- Metoclopramide: May reduce rotigotine effect
- Antihypertensives: May enhance hypotensive effect
- Other Sedatives: Additive sedation
- CYP1A2 Inhibitors: May increase rotigotine levels (e.g., fluvoxamine)
¶ Dosing and Administration
| Step |
Dose |
Duration |
| Week 1 |
2 mg/24h |
7 days |
| Week 2 |
4 mg/24h |
7 days |
| Week 3 |
6 mg/24h |
7 days |
| Week 4 |
8 mg/24h |
Maintenance |
- Apply to clean, dry, intact skin
- Rotate application sites (abdomen, thigh, hip, flank, shoulder, upper arm)
- Keep patch in place for 24 hours
- Do not use heat (heating pads, hot bath) near patch
- Replace at same time each day
- Continuous Delivery: Avoids pulsatile receptor stimulation
- Reduced Side Effects: Lower rates of nausea and impulse control disorders
- Better Adherence: Once-daily application
- No Swallowing Issues: Suitable for patients with dysphagia
- More Stable Plasma Levels: More consistent symptom control
The study of Rotigotine (Neupro) For Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- {{cite journal | author=Wenzel RG et al. | title=Rotigotine transdermal patch for Parkinson disease | journal=Am J Health Syst Pharm | year=2009 }}
- {{cite journal | author=Poewe WH et al. | title=Rotigotine transdermal patch in Parkinson disease | journal=CNS Drugs | year=2010 }}
- {{cite journal | author=Oertel W et al. | title=Rotigotine transdermal patch in early Parkinson disease | journal=Neurology | year=2011 }}